Shire Announces Award Recipients for 2013 US ADHD Scholarship Program Scholarship Program designed for individuals with Attention-Deficit/Hyperactivity Disorder (ADHD) going on to higher education
PHILADELPHIA, July 18, 2013 /PRNewswire/ --
Shire, a global specialty biopharmaceutical company, has named the recipients of its 2013 US ADHD Scholarship Program. The program is for individuals in the United States diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) who are pursuing higher education at a college, vocational school, or technical school. Fifty award recipients have been selected from  applicants across the United States. The recipients were selected on the basis of an essay explaining how ADHD has impacted their lives, letters of recommendation, community service, and volunteer and extracurricular activities.
In 2011, Shire introduced the ADHD Scholarship Program and awarded 25 scholarships. Due to the tremendous response, Shire doubled the number of scholarships to 50 in 2012. Shire will offer 50 scholarships in 2013. The scholarship program is part of Shire's patient-centric approach that offers support to patients with ADHD and their caregivers.
The Shire ADHD Scholarship includes a $2,000 monetary award and a prepaid year of ADHD coaching services. The coaching services are intended to assist the recipients in their pursuit of higher education and are provided by the Edge Foundation. For more information on the program, please visit http://www.ShireADHDscholarship.com.
The 2013 winners are: Bates, Meagan, Delaware; Bowman, Christian, Maryland; Butler, Enamarie, Maryland; Carray, Mariah, California; Copeland, Lewis, Virginia; Craft, Joshua, Mississippi; Erwin, Emily, Nebraska; French, Gabriel, Kentucky; Gilliam, Zachary, Texas; Hansen, Mallory, New Jersey; Jirsa, Jessica, Missouri; Kriz, Connor, Kentucky; Kuebbing, Joseph, Kentucky; Larkin, Zachary, California; Lewis, Austin, Georgia; Luberda, Joshua, Virginia; Lukas, Christopher, Mississippi; Martin, Jacqueline, Alabama; Meek, Lauren, Washington, DC; Moses, Kristen, Illinois; Peterson, Ryan, New Hampshire; Ruiz, Jessica, California; Sanders, Jordan, Florida; Scalisi, David, California; Shelton, Stuart, Tennessee; Silva, Ryan; Louisiana; Stickney, Haley, Florida; VandeLune, Christopher, Illinois; Wesler, Katherine, Alabama.
The remainder of the 2013 recipients requested that their names not be publicized.
"I am proud to recognize the award recipients of the ADHD Scholarship Program," said Scott Applebaum, Senior Vice President of Shire's Neuroscience Business Unit. "The program received thousands of applications from individuals with ADHD who are pursuing higher education. The Shire team is thrilled to be able to help these individuals with both tuition assistance and ADHD coaching services."
Award recipients will be offered ADHD coaching from the Edge Foundation, which includes weekly sessions with trained ADHD coaches. The students set weekly goals and action plans to meet those goals and have e-mail and phone support from their coaches to help keep them on track.
"This program is in its third year and has now gone international to include students in Canada. Shire has consistently supported post-secondary students with ADHD, and has encouraged the growth of this program, which is now double in size to where we were when it started," said Robert Tudisco, Executive Director of the Edge Foundation. "We applaud Shire's continued and increased support for students with ADHD."
The Edge Foundation is a Seattle-based nonprofit organization that offers support for students with ADHD. The Edge Foundation's primary mission is to provide access to qualified, professional coaches for students with ADHD as part of their multimodal treatment program.
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
For further information please contact:
Gwen Fisher (firstname.lastname@example.org)
Charlotte Zang (email@example.com)
SOURCE Shire Pharmaceuticals Group